Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy

• BEGLEY CE, FAMULARI M, ANNEGERS JF et al.: The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia (2000) 41:342-351.
   PubMed Web of Science ®Google Scholar
• BORO A, HAUT S: Medical comorbidities in the treatment of epilepsy. Epilepsy Behav. (2003) 4(Suppl. 2):S2-S12.
   PubMedGoogle Scholar
• TOMSON T: Mortality in epilepsy. J. Neurol. (2000) 247:15-21.
   PubMed Web of Science ®Google Scholar
• LAMICTAL® (lamotrigine) prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA (2005).
   Google Scholar
• RAMBECK B, WOLF P: Lamotrigine clinical pharmacokinetics. Clin. Pharmacokinet. (1993) 25:433-443.
   PubMed Web of Science ®Google Scholar
• LINGAMANENI R, HEMMINGS HC: Effects of anticonvulsants on veratridine- and KCl-evoked glutamate release from rat cortical synaptosomes. Neurosci. Lett. (1999) 276:127-130.
   PubMed Web of Science ®Google Scholar
• STEFANI A, SPADONI F, BERNARDI G: Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp. Neurol. (1997) 147:115-122.
   PubMed Web of Science ®Google Scholar
• WANG S, SIHRA TS, GEAN PW: Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport (2001) 12:2255-2258.
   PubMed Web of Science ®Google Scholar
• CALABRESI P, CENTONZE D, MARFIA GA et al.: An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. Br. J. Pharmacol. (1999) 126:689-696.
   PubMed Web of Science ®Google Scholar
• YAU MK, GARNETT WR, WARGIN WA et al.: A single-dose, dose-proportionality, and bioequivalence study of lamotrigine in normal volunteers. Epilepsia (1991) 32(Suppl. 3):S8.
   Google Scholar
• YUEN WC, PECK AW: Lamotrigine pharmacokinetics: oral and IV infusion in man. Br. J. Clin. Pharmacol. (1988) 26:242.
   Web of Science ®Google Scholar
• GARNETT WR: Lamotrigine: pharmacokinetics. J. Child Neurol. (1997) 12(Suppl. 1):S10-S15.
   PubMedGoogle Scholar
• ELWES RD, BINNIE CD: Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin, and oxcarbazepine. Clin. Pharmacokinet. (1996) 30:403-415.
   PubMed Web of Science ®Google Scholar
• COHEN AF, LAND GS, BREIMER DD et al.: Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther. (1987) 42:535-541.
   PubMed Web of Science ®Google Scholar
• PETRENAITE V, SABERS A, HANSEN-SCHWARTZ J: Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. (2005) 65:185-188.
   PubMed Web of Science ®Google Scholar
• PENNELL PB, NEWPORT DJ, STOWE ZN et al.: The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology (2004) 62:292-295.
   PubMed Web of Science ®Google Scholar
• ÖHMAN I, VITOLS S, TOMSON T: Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia (2000) 41:709-713.
   PubMed Web of Science ®Google Scholar
• WEINTRAUB D, BUCHSBAUM R, RESOR SR Jr et al.: Effect of antiepileptic drug comedication on lamotrigine clearance. Arch. Neurol. (2005) 62:1432-1436.
   PubMed Web of Science ®Google Scholar
• THEIS JG, SIDHU J, PALMER J et al.: Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology (2005) 30:2269-2274.
   PubMed Web of Science ®Google Scholar
• DOOSE DR, BRODIE MJ, WILSON EA et al.: Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia (2003) 44:917-922.
   PubMed Web of Science ®Google Scholar
• JAWAD S, YUEN WC, PECK AW et al.: Lamotrigine: single-dose pharmacokinetics and initial 1-week experience in refractory epilepsy. Epilepsy Res. (1987) 1:194-201.
   PubMed Web of Science ®Google Scholar
• JAWAD S, RICHENS A, GOODWIN G et al.: Controlled trial of lamotrigine for refractory partial seizures. Epilepsia (1989) 30:356-363.
   PubMed Web of Science ®Google Scholar
• LOISEAU P, YUEN AWC, DUCHE B et al.: A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res. (1998) 7:136-145.
   Google Scholar
• BESAG FM, BERRY DJ, POOL F et al.: Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia (1998) 39:183-187.
   PubMed Web of Science ®Google Scholar
• GIDAL BE, RUTECKI P, SHAW R et al.: Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. Epilepsy Res. (1997) 28:207-211.
   PubMed Web of Science ®Google Scholar
• ANDERSON GD, YAU MK, GIDAL BE et al.: Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin. Pharmacol. Ther. (1996) 60:145-156.
   PubMed Web of Science ®Google Scholar
• MATARINGA MI, MAY TW, RAMBECK B: Does lamotrigine influence valproate concentrations? Ther. Drug Monit. (2002) 24:631-636.
   PubMed Web of Science ®Google Scholar
• REIMERS A, SKOGVOLL E, SUND JK et al.: Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J. Clin. Psychopharmacol. (2005) 25:342-348.
   PubMed Web of Science ®Google Scholar
• ODISHAW J, CHEN C: Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy (2000) 20:1448-1453.
   PubMed Web of Science ®Google Scholar
• SIDHU J, JOB S, BULLMAN J et al.: Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br. J. Clin. Pharmacol. (2006) 61:420-426.
   PubMed Web of Science ®Google Scholar
• CHEN C, VERONESE L, YIN Y: The effects of lamotrigine on the pharmacokinetics of lithium. Br. J. Clin. Pharmacol. (2000) 50:193-195.
   PubMed Web of Science ®Google Scholar
• SABERS A, BUCHHOLT JM, ULDALL P et al.: Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. (2001) 47:151-154.
   PubMed Web of Science ®Google Scholar
• SABERS A, ÖHMAN I, CHRISTENSEN J et al.: Oral contraceptives reduce lamotrigine plasma levels. Neurology (2003) 61:570-571.
   PubMed Web of Science ®Google Scholar
• SIDHU J, JOB S, SINGH S et al.: The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br. J. Clin. Pharmacol. (2006) 61:191-199.
   PubMed Web of Science ®Google Scholar
• REIMERS A, HELDE G, BRODTKORB E: Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia (2005) 46:1414-1417.
   PubMed Web of Science ®Google Scholar
• BITON V, MIRZA W, MONTOURIS G et al.: Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology (2001) 56:172-177.
   PubMed Web of Science ®Google Scholar
• MORRELL MJ, ISOJÄRVI J, TAYLOR AE: Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res. (2003) 54:189-199.
   PubMed Web of Science ®Google Scholar
• BESAG FM: Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin. Drug Saf. (2004) 3:1-8.
   PubMedGoogle Scholar
• ALDENKAMP AP, BAKER G: A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav. (2001) 2:85-91.
   PubMed Web of Science ®Google Scholar
• UVEBRANT P, BAUZIENE PR: Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics (1994) 25:284-289.
   PubMed Web of Science ®Google Scholar
• EDWARDS KR, SACKELLARES JC, VUONG A et al.: Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav. (2001) 2:28-36.
   PubMed Web of Science ®Google Scholar
• MARTIN R, KUZNIECKY R, HO S et al.: Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology (1999) 52:321-327.
   PubMed Web of Science ®Google Scholar
• KOCKELMANN E, ELGER CE, HELMSTAEDTER C: Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy Behav. (2004) 5:716-721.
   PubMed Web of Science ®Google Scholar
• BLUM D, MEADOR K, BITON V et al.: Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology (2006) 67:400-406.
   PubMed Web of Science ®Google Scholar
• GILLIAM F, VAZQUEZ B, SACKELLARES JC et al.: An active-control trial of lamotrigine monotherapy for partial seizures. Neurology (1998) 51:1018-1025.
   PubMed Web of Science ®Google Scholar
• BITON V, SACKELLARES JC, VUONG A et al.: Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology (2005) 65:1737-1743.
   PubMed Web of Science ®Google Scholar
• MESSENHEIMER JA, MULLENS EL, GIORGI L et al.: Safety review of adult clinical trial experience with lamotrigine. Drug Saf. (1998) 18:281-296.
   PubMed Web of Science ®Google Scholar
• GUBERMAN AH, BESAG FMC, BRODIE MJ et al.: Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia (1999) 40:985-991
   PubMed Web of Science ®Google Scholar
• MESSENHEIMER JA: Rash in adult and pediatric patients treated with lamotrigine. Can. J. Neurol. Sci. (1998) 25:S14-S18.
   Google Scholar
• BOWDEN CL, ASNIS GM, GINSBERG LD et al.: Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf. (2004) 27:173-184.
   PubMed Web of Science ®Google Scholar
• TENNIS P, ELDRIDGE RR; INTERNATIONAL LAMOTRIGINE PREGNANCY REGISTRY SCIENTIFIC ADVISORY COMMITTEE: Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia (2002) 43:1161-1167.
   PubMed Web of Science ®Google Scholar
• SABERS A, DAM M, A-ROGVI-HANSEN B et al.: Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol. Scand. (2004) 109:9-13.
   PubMed Web of Science ®Google Scholar
• QUATTRINI A, ORTENZI A, PAGGI A et al.: Lamotrigine and pregnancy [letter]. Ital. J. Neurosci. (1996) 17:441.
   PubMedGoogle Scholar
• RAMBECK B, KURLEMANN G, STODIECK SRG et al.: Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur. J. Clin. Pharmacol. (1997) 51:481-484.
   PubMed Web of Science ®Google Scholar
• TOMSON T, ÖHMAN I, VITOLS S: Lamotrigine in pregnancy and lactation: a case report. Epilepsia (1997) 38:1039-1041.
   PubMed Web of Science ®Google Scholar
• ÖHMAN I, VITOLS S, TOMSON T: Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia (2000) 41:709-713.
   PubMed Web of Science ®Google Scholar
• TRAN TA, LEPPIK IE, BLESI K et al.: Lamotrigine clearance during pregnancy. Neurology (2002) 59:251-255.
   PubMed Web of Science ®Google Scholar
• CUNNINGTON M, TENNIS P; INTERNATIONAL LAMOTRIGINE PREGNANCY REGISTRY SCIENTIFIC ADVISORY COMMITTEE: Lamotrigine and the risk of malformations in pregnancy. Neurology (2005) 64:955-960.
   PubMed Web of Science ®Google Scholar
• HOLMES LB, WYSZYNSKI DF, BALDWIN EJ et al.: Increased risk for nonsyndromic cleft palate among infants exposed to lamotrigine during pregnancy. Abstract. Birth Defects Res. Part A Clin. Mol. Teratol. (2006) 76:318.
   Google Scholar
• MORROW J, RUSSELL A, GUTHRIE E et al.: Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry (2006) 77:193-198.
   PubMed Web of Science ®Google Scholar
• VAJDA FJE, EADIE MJ: Maternal valproate dosage and foetal malformations. Acta Neurol. Scand. (2005) 112:137-143.
   PubMed Web of Science ®Google Scholar
• CHONG E, DUPUIS LL: Therapeutic drug monitoring of lamotrigine. Ann. Pharmacother. (2002) 36:917-920.
   PubMed Web of Science ®Google Scholar
• GIDAL BE, SHETH R, PARNELL J et al.: Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res. (2003) 57:85-93.
   PubMed Web of Science ®Google Scholar
• SALE ME, NATARAJAN S, BITON V et al.: A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. Epilepsy Behav. (2005) 6:63-70.
   PubMed Web of Science ®Google Scholar
• SABERS AS, GRAM L: Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs (2000) 60:23-33.
   PubMed Web of Science ®Google Scholar
• LOTT RS: Lamotrigine: treatment of epilepsy in the elderly. Consult. Pharm. (2003) 18:979-992.
   PubMedGoogle Scholar

Website

• http://www.abstracts2view.com/aan/view.php?nu=AAN06L_P01.088MESSENHEIMER JA, WEIl J: Thirteen-year interim results from an international observational study of pregnancy outcomes following exposure to lamotrigine. Abstract P01-088. 2006 Annual Meeting of the American Academy of Neurology, San Diego, CA, USA. Accessed 17 April 2006.
   Google Scholar